Загрузка...
Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)
BACKGROUND: Eighty percent of children with steroid-sensitive nephrotic syndrome (SSNS) relapse within 2 years and 40–50% patients show frequently-relapsing nephrotic syndrome (FRNS). Patients showing a relapse within 6 months after initial remission are at high risk of FRNS. Since frequent predniso...
Сохранить в:
| Опубликовано в: : | BMC Nephrol |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6131840/ https://ncbi.nlm.nih.gov/pubmed/30200895 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-018-1033-z |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|